Literatur
- 1
Adams H A, Baumann G, Gänsslein A. et al .
Die Definitionen der Schockformen.
Intensivmed.
2001;
38
541-553
- 2
Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome,
and associated costs of care.
Crit Care Med.
2001;
29
1303-1310
- 3
Annane D, Sebille V, Charpentier C. et al .
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality
in patients with septic shock.
JAMA.
2002;
288
862-871
- 4
Belcher E, Mitchell J, Evans T.
Myocardial dysfunction in sepsis: no role for NO?.
Heart.
2002;
87
507-509
- 5
Bernard G R, Vincent J L, Laterre P F. et al .
Efficacy and safety of recombinant human activated protein C for severe sepsis.
N Engl J Med.
2001;
344
699-709
- 6
Bone R C, Sibbald W J, Sprung C L.
The ACCP-SCCM consensus conference on sepsis and organ failure.
Chest.
1992;
101
1481-1483
- 7
Brunkhorst F M, Karzai W, Reinhart K.
Aktuelle Aspekte zur Sepsisdiagnose.
Zentralbl Chir.
2002;
127
165-173
- 8
Dünser M, Wenzel V, Mayr A J, Hasibeder W R.
Arginin-Vasopressin im vasodilatatorischen Schock - Ein neuer Therapieansatz?.
Anaesthesist.
2002;
51
650-659
- 9
Finkel M S, Oddis C V, Jacob T D, Watkins S C, Hattler B G, Simmons R L.
Negative inotropic effects of cytokines on the heart mediated by nitric oxide.
Science.
1992;
257
387-389
- 10 Hamilton-Davies C, Mythen M G, Webb A R. Endotoxin immune status and protection
against multiple organ dysfunction syndrome in the surgical patient. Springer Berlin
In Vincent JL (Hrsg). 1996 Yearbook of Intensive Care and Emergency Medicine. 1
Aufl 1996: 24-38
- 11
Hotchkiss R S, Karl I E.
The pathophysiology and treatment of sepsis.
N Engl J Med.
2003;
348
138-150
- 12
Krishnagopalan S, Kumar A, Parrillo J E, Kumar A.
Myocardial dysfunction in the patient with sepsis.
Curr Opin Crit Care.
2002;
8
376-388
- 13
Kumar A, Haery C, Parrillo J E.
Myocardial dysfunction in septic shock.
Crit Care Clin.
2000;
16
251-287
- 14
Kumar A, Haery C, Parrillo J E.
Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular
dysfunction.
J Cardiothorac Vasc Anesth.
2001;
15
364-376
- 15
Kumar A, Krieger A, Symeoneides S, Kumar A, Parrillo J E.
Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide.
J Cardiothorac Vasc Anesth.
2001;
15
485-511
- 16
Matot I, Sprung C L.
Definition of sepsis.
Intensive Care Med.
2001;
27
S3-S9
(Suppl 1)
- 17
Meier-Hellmann A.
Katecholamintherapie in der Sepsis.
Anaesthesist.
2000;
49
1069-1076
- 18
Müller-Werdan U.
Akute septische Kardiomyopathie.
Internist.
1998;
39
467-478
- 19
Müller-Werdan U, Schumann H, Fuchs R. et al .
Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically
relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS)
or triggering serious cytotoxicity.
J Mol Cell Cardiol.
1997;
29
2915-2923
- 20
Müller-Werdan U, Schumann H, Loppnow H. et al .
Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect
in neonatal rat cardiomyocytes, but have different cardiodepressant profiles.
J Mol Cell Cardiol.
1998;
30
1027-1036
- 21 Müller-Werdan U, Werdan K. Prophylaxe und Therapie der akuten septischen Kardiomyopathie. Springer-Verlag
Heidelberg, New York, Berlin In Schuster HP und Werdan K (Hrsg). Intensivtherapie
bei Sepsis und Multiorganversagen. 3 Aufl 2000: 333-396
- 22
Ostermann H, Derigs H G, Heussel G. et al .
Sepsis in Neutropenie - Standardempfehlungen der Arbeitsgemeinschaft Infektiologie
in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie.
Dtsch Med Wochenschr.
1999;
124
S14-S17
(Suppl 1)
- 23 Parker M M. Cardiovascular function in septic shock. Springer Berlin In Vincent
JL (Hrsg). 1996 Yearbook of Intensive Care and Emergency Medicine. 1 Aufl 1996:
39-44
- 24
Parker M M, Shelhamer J H, Bacharach S L. et al .
Profound but reversible myocardial depression in patients with septic shock.
Ann Intern Med.
1984;
100
483-490
- 25
Parker M M, Suffredini A F, Natanson C, Schuette W.
Respones of left ventricular function in survivors and non-survivors of septic shock.
J Crit Care.
1989;
4
25
- 26
Parrillo J E, Burch C, Shelhamer J H, Parker M M, Natanson C, Schuette W.
A circulating myocardial depressant substance in humans with septic shock. Septic
shock patients with a reduced ejection fraction have a circulating factor that depresses
in vitro myocardial cell performance.
J Clin Invest.
1985;
76
1539-1553
- 27
Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P.
Effects of a nitric oxide synthase inhibitor in humans with septic shock.
Cardiovasc Res.
1994;
28
34-39
- 28
Price S, Anning P B, Mitchell J A, Evans T W.
Myocardial dysfunction in sepsis: mechanisms and therapeutic implications.
Eur Heart J.
1999;
20
715-724
- 29
Rangel-Frausto M S.
The epidemiology of bacterial sepsis.
Infect Dis Clin North Am.
1999;
13
299-312
- 30
Rangel-Frausto M S, Pittet D, Costigan M, Hwang T, Davis C S, Wenzel R P.
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective
study.
JAMA.
1995;
273
117-123
- 31
Reinhart K, Brunkhorst F M.
Die Sepsis.
Zentralbl Chir.
2002;
127
161-163
- 32
Reinhart K, Sakka S G, Meier-Hellmann A.
Haemodynamic management of a patient with septic shock.
Eur J Anaesthesiol.
2000;
17
6-17
- 33
Rivers E, Nguyen B, Havstad S. et al .
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med.
2001;
345
1368-1377
- 34
Schottmüller H.
Wesen und Behandlung der Sepsis.
Inn Med.
1914;
31
257-261
- 35
Schuster H P.
Schlussfolgerungen.
Intensivmed.
1989;
26
152-153
- 36 Schuster H P. Abriß der Pathophysiologie als Grundlage der Therapie. Springer
Berlin In Schuster HP (Hrsg). Intensivtherapie bei Sepsis und Multiorganversagen.
2 Aufl 1996: 23-42
- 37
Tsuneyoshi I, Kanmura Y, Yoshimura N.
Nitric oxide as a mediator of reduced arterial responsiveness in septic patients.
Crit Care Med.
1996;
24
1083-1086
- 38
Vincent J L.
Cardiovascular alterations in septic shock.
J Antimicrob Chemother.
1998;
41
9-15
(Suppl A)
- 39
Vincent J L.
Hemodynamic support in septic shock.
Intensive Care Med.
2001;
27
S80-S92
(Suppl 1)
- 40
Vincent J L, Moreno R, Takala J. et al .
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.
On behalf of the Working Group on Sepsis-Related Problems of the European Society
of Intensive Care Medicine.
Intensive Care Med.
1996;
22
707-710
- 41
Vincent J L, Zhang H, Szabo C, Preiser J C.
Effects of nitric oxide in septic shock.
Am J Respir Crit Care Med.
2000;
161
1781-1785
- 42 Walley K R. Mechanisms of decreased cardiac function in sepsis. Springer Berlin
In Vincent JL (Hrsg). 1997 Yearbook of Intensive Care and Emergency Medicine 1997:
243-255
- 43
Walmrath D, Grimminger F, Seeger W.
Schwere Sepsis - Neue Therapieverfahren.
Internist.
2001;
42
1619-1630
- 44
Wilson R F, Thal A P, Kindling P H, Grifka T, Ackerman E.
Hemodynamic measurement in septic shock.
Ann Surg.
1965;
91
121-129
Priv.-Doz. Dr. med. Uwe Janssens
Abteilung Innere Medizin 1, Caritas Krankenhaus
Uhlandstraße 7
97980 Bad Mergentheim
Phone: 07931/582100
Fax: 07931/582190
Email: uwe.janssens@ckbm.de
